Streptozotocin For Metastatic Malignant-Melanoma

Streptozotocin was administered at a dose of 500 mg/m2/day by continuous infusion for 120 hours to 14 patients with advanced malignant melanoma. No responses were observed in this group of patients and the median survival for the entire group was 2 months. At the dose and schedule delivered, streptozotocin is inactive against malignant melanoma.